Nifty IT Bottoming? Anand James Recommends SURYAROSNI, CHOLAFIN Buys
Analyzing: “Nifty IT bottoming out? Anand James on the expiry outlook, pharma profit-booking, and 2 stocks to buy this week” by et_markets · 25 May 2026, 9:52 AM IST (21 days ago)
What happened
Anand James from Geojit Investments predicts a Nifty breakout above 23,700 for the monthly expiry week. He highlights early signs of a bottom in the Nifty IT index, suggesting a potential turnaround for the sector. Conversely, he anticipates profit booking in the Pharma sector, which has seen significant gains recently.
Why it matters
This analysis provides crucial short-term directional cues for the broader market (Nifty) and specific sector rotations. A Nifty breakout could signal broader market strength, while the IT sector's potential recovery could shift investor focus. The warning on Pharma profit booking is vital for traders holding positions in that sector.
Impact on Indian markets
The Nifty IT index (e.g., TCS, INFY, WIPRO) could see positive momentum if the bottoming out trend confirms. Pharma stocks (e.g., SUNPHARMA, DRREDDY, CIPLA) might experience selling pressure due to profit booking. Surya Roshni (SURYAROSNI) and Cholamandalam Investment (CHOLAFIN) are specifically recommended for short-term buying, indicating potential upside for these individual stocks.
What traders should watch next
Traders should monitor Nifty's movement around the 23,700 level for a confirmed breakout. Observe the Nifty IT index for sustained upward momentum and volume. For Pharma, watch for increased selling pressure and support levels. Keep an eye on the performance of SURYAROSNI and CHOLAFIN for confirmation of the technical recommendations.
Key Evidence
- •Anand James expects Nifty to attempt a range breakout above 23,700.
- •He highlighted early bottoming signs in the Nifty IT index.
- •He warned of near-term profit booking in Pharma stocks.
- •He shared bullish technical views on Surya Roshni and Cholamandalam Investment for short-term trading.
- •Risk flag: Unexpected positive news flow (e.g., new drug approvals, strong quarterly results) could negate profit booking.
Affected Stocks
Recommended for short-term buy based on technical views.
Recommended for short-term buy based on technical views.
Showing early signs of bottoming out, indicating potential recovery.
Expected to see near-term profit booking.
People in this Story
Sources and updates
AI-powered analysis by
Anadi Algo News